Introduction {#S1}
============

Uncontrolled hypertension (HTN) is the most common cause of spontaneous intracerebral hemorrhage (ICH) ([@B1], [@B2]). Hypertensive ICH is a type of stroke with intraparenchymal bleeding from hypertensive damage to blood vessel walls. Chronic HTN produces microangiopathy characterized by lipohyalinosis, fibrinoid necrosis, and development of Charcot--Bouchard aneurysms, affecting penetrating arteries throughout the brain. The predilection sites for hypertensive ICH include the basal ganglia (40--50%), lobar regions (20--50%), thalamus (10--15%), pons (5--12%), cerebellum (5--10%), and other brainstem sites (1--5%) ([@B3], [@B4]).

Data from numerous studies have identified high systolic blood pressure (SBP) as the major risk factor for ICH ([@B5]--[@B7]). SBP variability predicts poor outcome and neurological deterioration ([@B8]--[@B10]).

Two large randomized controlled trials have demonstrated that early intensive lowering of SBP to less than 140 mm Hg is safe without significant outcome impact ([@B11], [@B12]). Acute lowering of SBP to 140 mm Hg has been recommended for the management of spontaneous ICH ([@B13]).

However, it is challenging to promptly and effectively control SBP in patients at risk for resistant HTN ([@B14]--[@B17]). Resistant HTN is defined as blood pressure that remains above normal despite of concurrent use of three antihypertensive agents of different classes ([@B15], [@B16]). Data derived from cross-sectional studies and *post hoc* analyses of clinical trials have estimated the prevalence of resistant HTN to be about 8--15% of all patients being treated for HTN ([@B17], [@B18]). Currently, little is known about resistant HTN in patients with ICH. We sought to evaluate the potential role of resistant HTN in ICH.

Materials and Methods {#S2}
=====================

Patients {#S2-1}
--------

All consecutive ICH admissions at the University of California, Irvine Medical Center between November 2013 and October 2015 were reviewed retrospectively. The patient list was compiled by searching the electronic medical record using International Classification of Diseases Ninth Revision code 431 and by stroke center primary data collection for the AHA *Getting with the Guidelines registry*. We then conducted extensive chart review to identify those with hypertensive ICH.

Study Protocol {#S2-2}
--------------

The screening of hypertensive ICH is described in Figure [1](#F1){ref-type="fig"}. Exclusion criteria included death or comfort care within 72 h of admission, all non-hypertensive ICH, isolated intraventricular hemorrhage, and ICH with subdural hemorrhage. Non-hypertensive ICH was defined as primary ICH without clinical evidence of HTN during the hospital stay. Patients with both HTN and cerebral amyloid angiopathy (CAA) or coagulopathy were counted as hypertensive ICH.

![**Screening flowchart for patients with hypertensive intracerebral hemorrhage (ICH)**.](fneur-08-00184-g001){#F1}

Hypertensive ICH patients were divided into two groups: patients on four or more antihypertensive agents at discharge (resistant group) and patients on three or fewer antihypertensive agents (responsive group) per AHA guidelines ([@B15]).

The following demographics and medical history were collected for patients with hypertensive ICH: age, gender, race, body mass index (BMI), social history, medical history, and home medications (antiplatelet, anticoagulant, and antihypertensive agents). Clinical data collected were initial SBP and diastolic blood pressure, Glasgow coma scale score, hyponatremia, serum creatinine, urine protein, ICH location, ICH volume, midline shift, ICH score, ICH volume increase within 24 h, fever (\>38°C), pneumonia or other infections, deep vein thrombosis (DVT), seizure activities, rate of SBP \> 140 mm Hg during the intensive care unit (ICU) stay, ventilator support, external ventricular drainage (EVD), hematoma evacuation, use of hypertonic saline, duration of nicardipine infusion, length of stay (LOS) in the ICU and the hospital, disposition, number of oral antihypertensive agents, and modified Rankin Scale (mRS) score at discharge.

The ICH volume was calculated by the ABC/2 formula ([@B18]). The ICH score was estimated as previously described ([@B19]). ICH location was classified as deep (basal ganglia or thalamus), lobar, brain stem, or cerebellar. Midline shift was measured at the level of the septum pellucidum on CT scan. The outcome at discharge was divided into favorable functional recovery with mRS scores 0--3 and unfavorable functional recovery with mRS scores 4--6. Disposition was classified as self-destination (home or acute rehabilitation facility), dependent destination (acute care facility or skilled nursing facility), or death.

Statistical Analysis {#S2-3}
--------------------

Data analyses were performed using SPSS software. Categorical or dichotomous variables were expressed as frequency distribution and percentages. Group comparisons of variables were performed using the chi-square test, Fisher exact test, Student's *t*-test, or Mann--Whitney test as appropriate. Correlation analyses between variables were evaluated using Pearson's correlation coefficient. Multivariate linear regression was performed to assess the independent effect of variables. A *p* value of 0.05 or less was considered significant.

Results {#S3}
=======

Resistant HTN in Patients with ICH {#S3-1}
----------------------------------

Of the 244 ICH admissions, 152 patients met the inclusion criteria for hypertensive ICH and 92 patients were excluded due to early death, non-hypertensive causes, or unknown etiology (Figure [1](#F1){ref-type="fig"}). There were 48 patients (31.6%) in the resistant group and 104 (68.4%) in the responsive group.

Clinical Characteristics of Patients with Resistant and Responsive HTN {#S3-2}
----------------------------------------------------------------------

The baseline characteristics of the two study groups are shown in Table [1](#T1){ref-type="table"}. The patients with resistant HTN were associated with younger age, obstructive sleep apnea, chronic renal failure, higher initial blood pressures, increased serum creatinine, and proteinuria. There was no significant difference between the two groups in home use of antithrombotic and antihypertensive medications, ICH volume, location, or severity. After adjustment for age, race, and gender, logistic regression analysis showed that BMI (odds ratio, 1.073; 95% confidence interval, 1.005--1.145; *p* = 0.034) and proteinuria (odds ratio, 3.204; 95% confidence interval, 1.440--7.131; *p* = 0.004) were independently associated with resistant HTN.

###### 

**Clinical characteristics of ICH patients with resistant or responsive HTN**.

  Variables                       Resistant group (*n* = 48)   Responsive group (*n* = 104)   *p* Value
  ------------------------------- ---------------------------- ------------------------------ ---------------------------------------
  Age (years)                     58.0 (52.0, 67.8)            63.0 (51.0, 76.8)              0.041[\*](#tfn1){ref-type="table-fn"}
  Male                            30 (62.5)                    63 (60.6)                      0.821
  Race                                                                                        0.445
   Hispanic American              22 (45.8)                    48 (46.2)                      
   Non-Hispanic American          12 (25.0)                    29 (27.9)                      
   Asian-American                 9 (18.8)                     23 (22.1)                      
   African-American               5 (10.4)                     4 (3.8)                        
  Smoking                         7 (14.6)                     16 (15.4)                      0.930
  Alcohol use                     8 (16.7)                     15 (14.4)                      0.720
  Diabetes                        16 (33.3)                    32 (30.8)                      0.752
  Hyperlipidemia                  19 (39.6)                    40 (38.5)                      0.895
  Cardiovascular events           11 (22.9)                    13 (12.5)                      0.102
  OSA                             8 (16.7)                     6 (5.8)                        0.039[\*](#tfn1){ref-type="table-fn"}
  Chronic renal failure           13 (27.1)                    10 (9.6)                       0.005[\*](#tfn1){ref-type="table-fn"}
  Use of antiplatelet agents      11 (22.9)                    23 (22.1)                      0.912
  Use of anticoagulation agents   4 (8.3)                      10 (9.6)                       1.000
  Use of anti-HTN medications     25 (52.1)                    44 (42.3)                      0.260
  Initial GCS                                                                                 0.501
   9--15                          38 (79.2)                    87 (83.7)                      
   3--8                           10 (20.8)                    17 (16.3)                      
  Initial SBP (mm Hg) in ED       201.5 (186.5, 223.8)         180.0 (157.3, 200.0)           0.001[\*](#tfn1){ref-type="table-fn"}
  Initial DBP (mm Hg) in ED       99.5 (90.0, 123.0)           95.0 (79.0, 106.8)             0.016[\*](#tfn1){ref-type="table-fn"}
  BMI (kg/m^2^)                   27.8 (24.1, 33.2)            26.0 (23.0, 29.7)              0.010[\*](#tfn1){ref-type="table-fn"}
  Serum creatinine (mg/dL)        1.0 (0.7, 1.5)               0.8 (0.6, 1.0)                 0.008[\*](#tfn1){ref-type="table-fn"}
  Proteinuria                     28 (58.3)                    35 (33.7)                      0.004[\*](#tfn1){ref-type="table-fn"}
  Initial ICH volume (mL)         17.4 (5.5, 32.1)             11.8 (4.7, 21.6)               0.055
  Midline shift (mm)              0.0 (0.0, 4.9)               0.0 (0.0, 3.0)                 0.105
  ICH location                                                                                0.581
   Deep                           28 (58.3)                    69 (66.3)                      
   Lobar                          14 (29.2)                    21 (20.3)                      
   Brain stem                     4 (8.3)                      7 (6.7)                        
   Cerebellum                     2(4.2)                       7 (6.7)                        
  ICH score                                                                                   0.486
   0--2                           41 (85.4)                    84 (80.8)                      
   3--5                           7 (14.6)                     20 (19.2)                      

*BMI, body mass index; DBP, diastolic blood pressure; ED, emergency department; GCS, Glasgow coma scale; ICH, intracerebral hemorrhage; IQR, interquartile range; OSA, obstructive sleep apnea; SBP, systolic blood pressure; HTN, hypertension*.

*Variables are presented as *n* (%) in nominal data or median (IQR) in continuous data*.

*\*p \< 0.05*.

Antihypertensive Therapy {#S3-3}
------------------------

Patients with SBP \> 140 mm Hg were initially treated with labetalol or hydralazine 10 mg iv *pro re nata* and nicardipine infusion 2.5--15 mg/h. The intravenous medications were then quickly transitioned to oral antihypertensive agents, starting in the ICU. The commonly used oral antihypertensive agents included calcium channel blocker (CCB) amlodipine, angiotensin-converting enzyme inhibitor (ACE-I) lisinopril or benazepril, angiotensin II receptor blocker (ARB) losartan, diuretics hydrochlorothiazide or spironolactone, β-blocker metoprolol, α/β-blocker labetalol or carvedilol, central α agonist clonidine, and vasodilator hydralazine. The oral antihypertensive agents taken by patients at hospital discharge are shown in Table [2](#T2){ref-type="table"}. Approximately 29.2% (14/48) of patients with resistant HTN needed five or more antihypertensive agents. Patients with resistant HTN were more likely to be taking CCB, ACE-I, α/β blocker, diuretics, vasodilator, and central α-agonist than the responsive group.

###### 

**The use of antihypertensive agents in resistant and responsive groups**.

  Antihypertensive agents   Resistant group (*n* = 48)   Responsive group (*n* = 104)   *p* Value
  ------------------------- ---------------------------- ------------------------------ ---------------------------------------
  CCB                       42 (87.5)                    61 (58.7)                      0.001[\*](#tfn2){ref-type="table-fn"}
  ACE-I                     40 (83.3)                    68 (65.4)                      0.023[\*](#tfn2){ref-type="table-fn"}
  α/β Blocker               32 (66.7)                    37 (35.6)                      0.001[\*](#tfn2){ref-type="table-fn"}
  Diuretics                 23 (47.9)                    11 (10.6)                      0.001[\*](#tfn2){ref-type="table-fn"}
  β Blocker                 15 (31.3)                    25 (20.0)                      0.348
  Vasodilator               31 (64.6)                    8 (7.7)                        0.001[\*](#tfn2){ref-type="table-fn"}
  Central α-agonist         13 (27.1)                    6 (5.8)                        0.001[\*](#tfn2){ref-type="table-fn"}
  ARB                       8 (16.7)                     11 (10.6)                      0.291

*CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker*.

*\*p \< 0.05*.

Medical Complications, Interventions, and Outcome {#S3-4}
-------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, patients with resistant HTN were more likely to have fever, hyponatremia, and non-respiratory infections than those with responsive HTN. Despite higher initial blood pressures (Table [1](#T1){ref-type="table"}) and a higher rate of SBP \> 140 mm Hg (37.2 vs 25.2%; *p* = 0.001) (Table [3](#T3){ref-type="table"}) in the resistant group, there was no significant difference in average increase of the ICH volume at 24 h (3 ± 6.3 vs 4 ± 3.8). There was no difference in pneumonia, seizure activities, or DVT between the two groups.

###### 

**Clinical features and outcome of resistant and responsive groups**.

  Variables                          Resistant group (*n* = 48)   Responsive group (*n* = 104)   *p* Value                               OR or AD (95% CI)
  ---------------------------------- ---------------------------- ------------------------------ --------------------------------------- ---------------------
  Fever                              20 (41.7)                    24 (23.1)                      0.019[\*](#tfn3){ref-type="table-fn"}   2.38 (1.14, 4.96)
  Hyponatremia                       7 (14.6)                     4 (3.8)                        0.018[\*](#tfn3){ref-type="table-fn"}   4.27 (1.19, 15.37)
  Pneumonia                          10 (20.8)                    12 (11.5)                      0.130                                   2.02 (0.80, 5.07)
  Other infections                   12 (25.0)                    12 (11.5)                      0.034[\*](#tfn3){ref-type="table-fn"}   2.56 (1.05, 6.21)
  Deep vein thrombosis               2 (4.2)                      4 (3.8)                        1.000                                   1.09 (0.19, 6.15)
  Seizure                            2 (4.2)                      6 (5.8)                        1.000                                   0.71 (0.14, 3.65)
  ICH volume increase at 24 h        3 (6.3)                      4 (3.8)                        0.679                                   1.67 (0.36, 7.76)
  External ventricular drainage      7 (14.6)                     12 (11.5)                      0.598                                   1.31 (0.48, 3.57)
  Ventilator support                 23 (47.9)                    24 (23.1)                      0.002[\*](#tfn3){ref-type="table-fn"}   3.07 (1.48, 6.35)
  Use of hypertonic saline           14 (29.2)                    14 (13.5)                      0.020[\*](#tfn3){ref-type="table-fn"}   2.65 (1.14, 6.13)
  Hematoma evacuation                9 (18.8)                     7 (6.7)                        0.025[\*](#tfn3){ref-type="table-fn"}   3.20 (1.11, 9.19)
  Rate of SBP \> 140/SBP \< 140      37.2 (27.5, 53.5)            25.2 (15.9, 36.1)              0.001[\*](#tfn3){ref-type="table-fn"}   12.93 (7.97, 17.89)
  Rate of DBP \> 90/DBP \< 90        2.5 (0.5, 5.3)               1.6 (0.0, 4.2)                 0.048[\*](#tfn3){ref-type="table-fn"}   1.58 (−0.73, 3.89)
  Duration of nicardipine drip (h)   81.8 (41.0, 172.9)           59.0 (32.8, 111.6)             0.039[\*](#tfn3){ref-type="table-fn"}   38.90 (6.52, 71.28)
  LOS in the ICU (days)              4.2 (1.9, 9.4)               2.1 (1.3, 4.7)                 0.007[\*](#tfn3){ref-type="table-fn"}   2.30 (0.42, 4.19)
  LOS in the hospital (days)         11.5 (6.3, 16.8)             7.0 (5.0, 11.0)                0.003[\*](#tfn3){ref-type="table-fn"}   3.77 (0.02, 7.52)
  SBP at discharge (mm Hg)           134.5 (125.3, 146.0)         131.0 (119.0, 137.8)           0.003[\*](#tfn3){ref-type="table-fn"}   7.32 (2.45, 12.20)
  DBP at discharge (mm Hg)           70.5 (61.3, 79.5)            69.0 (61.0, 78.5)              0.567                                   1.13 (−2.76, 5.02)
  mRS at discharge                                                                               0.559                                   0.81 (0.40, 1.65)
   0--3                              17 (35.4)                    42 (40.4)                                                              
   4--6                              31 (64.6)                    62 (59.6)                                                              
  Disposition                                                                                    0.825                                   
   Self-destination                  22 (45.8)                    53 (51.0)                                                              
   Dependent destination             22 (45.8)                    44 (42.3)                                                              
   Death                             4 (8.4)                      7 (6.7)                                                                

*AD, absolute difference; CI, confidence interval; DBP, diastolic blood pressure; LOS, length of stay; ICH, intracerebral hemorrhage; ICU, intensive care unit; IQR, interquartile range; mRS, modified Rankin scale; OR, odds ratio; SBP, systolic blood pressure*.

*Variables are presented as *n* (%) in nominal data or median (IQR) in continuous data*.

*\*p \< 0.05*.

More patients with resistant HTN required intensive interventions such as ventilator support, hypertonic saline therapy, hematoma evacuation, and nicardipine infusion than the responsive group (Table [3](#T3){ref-type="table"}).

The resistant group also had significantly longer LOS in the ICU (4.2 vs 2.1 days; *p* = 0.007) and hospital (11.5 vs 7.0 days; *p* = 0.003) than that of the responsive group.

Multivariate linear regression analysis showed that fever (β coefficient = −0.306; *t* = −3.908; *p* = 0.001), ventilator support (β coefficient = −0.280; *t* = −3.840; *p* = 0.001), and hematoma evacuation (β coefficient = −0.126; *t* = −2.042; *p* = 0.043) were associated with longer LOS in the ICU. After risk adjustment for fever, hyponatremia, infections, ICH score, midline shift, ventilator support, and hematoma evacuation, the rate of SBP \> 140 mm Hg (β coefficient = 0.267; *t* = 4.536; *p* = 0.001) and the duration of nicardipine infusion (β coefficient = 0.418; *t* = 7.040; *p* = 0.001) were shown to be independently associated with LOS in the ICU.

There was no significant difference between the two groups in functional outcome (odds ratio, 0.81; 95% confidence interval, 0.40--1.65; *p* = 0.559) and disposition at hospital discharge (*p* = 0.825).

Discussion {#S4}
==========

In this single-center cohort, resistant HTN was found in 31.6% patients with hypertensive ICH. It was independently associated with higher BMI and proteinuria. Higher BMI might be a risk factor for resistant HTN, while proteinuria likely reflects end organ damage from chronic HTN. Of note, resistant HTN is seen in only 8--15% of the general hypertensive population ([@B16], [@B17]). There appears to be a higher prevalence of resistant HTN in patients with ICH than in the general hypertensive population. Of note, majority of our ICH patients were Hispanic and Asian. Some of them had never seen a doctor in the past. That may explain the higher prevalence of resistant HTN in our ICH population. There were also significant numbers of patients with lobar or cerebellar hemorrhage in our cohort. Although most of these patients were young and unlikely to have CAA, we cannot rule out the possibility of underlying CAA in some patients.

Medical complications such as fever and infections were reported to increase LOS after ICH ([@B20], [@B21]). In the current study, we demonstrated that patients with resistant HTN had higher rates of medical complications, greater requirement for intensive interventions in the ICU, and longer LOS in the ICU and hospital than patients with responsive HTN. After risk adjustment, the rates of SBP \> 140 mm Hg and the duration of nicardipine infusion were independently associated with LOS in the ICU. With intensive BP lowering in both groups, there was no significant difference in average increase of the ICH volume at 24 h and functional outcome at hospital discharge.

Our preliminary findings have a number of implications. First, given higher prevalence of resistant HTN in patients with ICH than in the general hypertensive population, resistant HTN may be a significant risk factor for ICH and should be treated aggressively in the outpatient setting.

Second, 68.4% of hypertensive ICH patients had responsive HTN, and approximately 60% of these patients did not require intensive interventions such as EVD, hematoma evacuation, or ventilation support (Table [3](#T3){ref-type="table"}). These findings support the view that patients with minor ICH can be safely monitored in the step-down unit ([@B22]--[@B24]).

Third, longer LOS in the ICU is associated with significantly higher health-care costs and burdens on patients and their families ([@B25], [@B26]). In view of the lack of outcome benefit from aggressive medical and surgical interventions ([@B11], [@B12], [@B27]--[@B29]), it appears that now it is the time to assess resource utilization in patients with hypertensive ICH. Since higher rates of SBP and prolonged duration of nicardipine infusion were associated with longer LOS in the ICU, early transition from intravenous nicardipine infusion to oral antihypertensive agents in the ICU may potentially reduce LOS and health-care costs.

Finally, little is known about effective management of resistant HTN after ICH. CCB and ACE-I or ARB are widely accepted as first- and second-line drugs for resistant HTN ([@B14]). However, the choice of third- and fourth-line antihypertensive agents varies greatly in the management of hypertensive ICH. Hydrochlorothiazide may not be appropriate for patients with large ICH due to the risk of hyponatremia and worsening perihematoma edema. In a recent randomized trial, spironolactone was shown to be very effective in patients with resistant HTN ([@B30]). We have successfully used spironolactone and α/β-blocker labetalol as the third- and fourth-line oral agents to control resistant HTN and to wean off nicardipine infusion promptly. A proposed oral antihypertensive titration protocol is shown in Figure [2](#F2){ref-type="fig"}.

![**Oral antihypertensive titration protocol for hypertensive intracerebral hemorrhage (ICH)**.](fneur-08-00184-g002){#F2}

Our study has limitations. First, it was retrospective in nature, and resistant HTN was defined after ICH in the acute care setting. In the acute phase, patients with ICH may have significantly elevated BP due to a stress response. However, stress-induced reactive HTN usually responds to antihypertensive therapy promptly and is unlikely to require more than three oral agents for BP control. Second, given small sample size, the study is insufficiently powered to show significant outcome differences between resistant and responsive groups. The lack of 90-day outcome data made it impossible to know the long-term impact of resistant HTN on functional recovery. A larger sample size study with 90-day outcome data is needed to address the issue.

In summary, resistant HTN may be more prevalent in patients with ICH than in the general hypertensive population. Our data show that resistant HTN increases intensive interventions and LOS in the ICU without significant impact on short-term functional outcome at hospital discharge.
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